Literature DB >> 11965836

Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia.

Pichaya Sarasombath1, Kenneth Sumida, David A Kaku.   

Abstract

A 79 year-old man was treated with Interferon alpha for chronic myelogenous leukemia and developed severe parkinsonism that resolved after Interferon alpha was stopped. Carbidopa-levodopa was associated with early improvement, but discontinuation did not result in worsening of the parkinsonism.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11965836

Source DB:  PubMed          Journal:  Hawaii Med J        ISSN： 0017-8594


  5 in total

Review 1.  Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

Authors:  Jennifer C Felger; Andrew H Miller
Journal:  Front Neuroendocrinol       Date:  2012-09-21       Impact factor: 8.606

Review 2.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

Review 3.  Neuropsychiatric adverse effects of interferon-alpha: recognition and management.

Authors:  Charles L Raison; Marina Demetrashvili; Lucile Capuron; Andrew H Miller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease.

Authors:  Darcy Litteljohn; Emily Mangano; Melanie Clarke; Jessica Bobyn; Kerry Moloney; Shawn Hayley
Journal:  Parkinsons Dis       Date:  2010-12-30

5.  Allosteric coupling between Mn2+ and dsDNA controls the catalytic efficiency and fidelity of cGAS.

Authors:  Richard M Hooy; Guido Massaccesi; Kimberly E Rousseau; Michael A Chattergoon; Jungsan Sohn
Journal:  Nucleic Acids Res       Date:  2020-05-07       Impact factor: 16.971
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.